Sign up to save your podcasts
Or
Share MediCom Oncology Clinical Pearls Podcasts
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
MediCom Oncology Clinical Pearls Podcasts
By MediCom OncologyScience
MediCom Oncology Clinical Pearls Podcasts episodes
- Third-generation FLT3 inhibitors in clinical developmentDr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.3 min
- CAR T case study in acute myeloid leukemiaDr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.6 min
- Key considerations when prescribing midostaurin with a strong CYP3A4 inhibiDr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.3 min
- How to proceed with a patient who presents with idiopathic cytopenia of undetermined significanceIn this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).4 min
- When to consider iron chelation therapy for a transplant-eligible patientListen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.4 min
- 53-year-old woman presenting with severe fatigue and bruisingHematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.4 min
- New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapyDr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.4 min
- What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.3 min
- Predictors of response to lenalidomide in a non-del(5q) MDS patientListen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.4 min
- What are the pros and cons of radiation therapy?Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.3 min
About MediCom Oncology Clinical Pearls Podcasts
From the publisher's feed
MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company.
Podcasts are intended for licensed adult healthcare professionals (HCPs). HCPs should exercise professional judgment in evaluating content, and confirm information before implementing treatment or practice-related changes. Podcasts do not provide medical advice to patients.